Abstract Details

Title Investigating the Role of Artmaking as a Therapeutic Tool in the Treatment of Chronic Migraine

Topic Headache

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 13-007

Objective This study sought to investigate the efficacy of artmaking as a complementary intervention to pharmacologic therapy in treating chronic migraine.

Background Migraine is a leading cause of disability worldwide, and often leaves patients and physicians frustrated due to its complex nature. Although treatments exist for the disorder, its comorbidity with anxiety may offer novel routes for developing effective therapies with minimal side effects. Art therapy has been shown to be a successful tool in the treatment of anxiety, however, artmaking has not been explored as a treatment for migraine.

Design/Methods

During this 12-week study, thirty-five participants were divided into experimental and control groups. Experimental participants received art supplies upon enrollment and were instructed to draw what their most recent migraine felt like daily for the study's duration. The artwork was collected on a weekly basis and evaluated. Participants in both groups recorded their headache activity via a daily log. This data was collected weekly and evaluated following a Per Protocol analysis, upon study completion. Both groups completed longitudinal surveys, which were administered in conjunction with the standard treatment regimen of Botox injections, to assess changes in their quality of life, functional capacity, and level of disability.

Results For participants who received Botox injections at weeks 0 and 12, there was a statistically significant decrease in HIT6 scores of 6.09 points in the experimental group as compared to the control group (p = 0.0371). The number of tension headaches, and the number of probable migraines, reported by the experimental group both significantly decreased by an average of 13% per week throughout the study (p = 0.0024 and p < 0.0001, respectively). These measures were pre-specified outcomes.

Conclusions

When coupled with an established medication regimen, artmaking may improve treatment outcomes of patients suffering from primary headache disorders. This preliminary study indicated further research is warranted.

Authors/Disclosures
Amanda E. Simon, MD (OHSU) PRESENTER	Dr. Simon has nothing to disclose.
	No disclosure on file
Christopher C. Gottschalk, MD (Yale Medicine (Neurology))	Dr. Gottschalk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Abbvie. Dr. Gottschalk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Lundbeck. Dr. Gottschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Gottschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Satsuma. Dr. Gottschalk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Spherix Global Insights. Dr. Gottschalk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theranica. Dr. Gottschalk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tonix. Dr. Gottschalk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Impel. Dr. Gottschalk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vectura Fertin. Dr. Gottschalk has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Headache Cooperative of the Northeast (HCNE). The institution of Dr. Gottschalk has received research support from Rehaler.

��ɫ��

��ɫ��